73P Cognitive toxicity of avapritinib: A case series
Avapritinib is a KIT and PDGFRA inhibitor with high potency against KIT D816V and PDGFRA D842V mutations, and is used primarily in advanced GIST with PDGFRA D842V mutation. In the landmark phase III VOYAGER trial, cognitive events of any grade were reported in 26% of patients treated with avapritinib (grade 3: 1.3%). It is hypothesised that inhibition of PDGFRβ may lead to disruption of the blood-brain barrier and accumulation of neurotoxic proteins.
Authors
- Andressa Bernardi (ORCID: https://orcid.org/0000-0001-5079-5866)
- Émilie Turcotte
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104387
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00